HLUN-B.CO Overview

Company Profile

Related stocks

HLUN-A.CO • Denmark

H. Lundbeck A/S A

43.8 DKK

6.51B USD 1Y +21.3%

ALKS • Ireland

Alkermes plc

40.61 USD

6.81B USD 1Y +27.3%

KNSA • United Kingdom

Kiniksa Pharmaceuticals Interna

79.78 USD

6.14B USD 1Y +105.6%

ROVI.MC • Spain

LABORATORIOS FARMACEUTICOS ROVI

58.05 EUR

3.33B USD 1Y -1.1%

IPN.PA • France

IPSEN

142.7 EUR

13.18B USD 1Y +20.7%

SOBI.ST • Sweden

Swedish Orphan Biovitrum AB

428.4 SEK

14.92B USD 1Y +35.3%

HIK.L • United Kingdom

HIKMA PHARMACEUTICALS PLC ORD S

1,612 GBp

4.41B USD 1Y -12.5%

ALM.MC • Spain

ALMIRALL S.A.

10.08 EUR

2.46B USD 1Y -15.5%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile

4 Metrics

Country

Denmark

Region

Europe

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High

5Y Volatility

30.2% p.a.

Max Drawdown (5Y)

-44.3%

Sharpe Ratio (5Y)

0.20

Beta Factor

0.24

Size Class

Large Cap

Notes & Warnings

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).

Exemplary balance sheet strength: Very solid ratio of equity to debt.

Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (30.2% p.a.).

Historical Stress Test: Maximum peak-to-trough drawdown of -44.3% in the extended horizon.